Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

BACKGROUND: This study sought to determine the safety of single agent capecitabine, a pro-drug of 5FU, in patients with metastatic non-pancreatic neuroendocrine tumours (NETs). METHODS: Multicentre phase II, first-line study design. Oral capecitabine was administered on days 1-14 of 3-week cycles. RESULTS: Treatment was safe and well tolerated. Common toxicities were diarrhoea and fatigue. CONCLUSION: The study provides evidence to support the use of capecitabine as a substitute for infusional 5FU in the management of NETs.

Original publication

DOI

10.1038/bjc.2011.76

Type

Journal article

Journal

Br J Cancer

Publication Date

29/03/2011

Volume

104

Pages

1067 - 1070

Keywords

Aged, Antimetabolites, Antineoplastic, Capecitabine, Deoxycytidine, Female, Fluorouracil, Humans, Male, Middle Aged, Neoplasm Metastasis, Neuroendocrine Tumors